Showing 1 – 20 of 148
Relevance | Newest | Oldest |
  • Effect of a Single Dose of Oral Opioid and Nonopioid Analgesics on Acute Extremity Pain in the Emergency Department: A Randomized Clinical Trial

    Abstract Full Text
    JAMA. 2017; 318(17):1661-1667. doi: 10.1001/jama.2017.16190

    This randomized clinical trial compares the efficacy of 4 oral combination analgesics among adult patients treated for moderate to severe acute extremity pain at 2 urban emergency departments in the United States.

  • JAMA October 11, 2017

    Figure: Opioid Use and Overdose and Fentanyl Drug Reports, 1999-2015

    aSource: National Center for Health Statistics at the US Centers for Disease Control and Prevention. WONDER online database: prescription opioid overdose deaths include fatal overdoses related to natural and semisynthetic opioids or methadone. Illicit opioid-related overdose deaths are related to heroin or synthetic nonmethadone opioids, and some overdose deaths are related to prescribed fentanyl or other prescribed synthetic opioids.bSource: Substance Abuse and Mental Health Services Administration. National Survey on Drug Use and Health. Dashed line from 1999 to 2005 (Drug Enforcement Administration. Automation of Reports and Consolidated Orders System: sales to pharmacies, hospitals, and practitioners for codeine, fentanyl, hydrocodone, hydromorphone, meperidine, methadone, morphine, and oxycodone. Paulozzi LJ, et al. MMWR Morb Mortal Wkly Rep. 2011;60:1487-1492). Solid line from 2006 to 2015 (QuintilesIMS estimates of opioid prescriptions dispensed in the United States to 59 000 pharmacies, representing 88% of US prescriptions. Guy GP Jr, et al. MMWR Morb Mortal Wkly Rep. 2017;66:697-704).dSource: Drug Enforcement Administration. Fentanyl, 2001-2015. The number of fentanyl drug reports reflects the number of encounters by law enforcement that tested positive for fentanyl. Therefore, fentanyl drug reports provide an indication of the available supply of illicitly manufactured fentanyl.
  • A New Abuse-Deterrent Opioid—Xtampza ER

    Abstract Full Text
    JAMA. 2016; 316(9):986-987. doi: 10.1001/jama.2016.9540

    This Medical Letter review summarizes a newly approved extended-release, abuse-deterrent capsule formulation of oxycodone for pain management.

  • Oxycodone for Cancer Pain in Adult Patients

    Abstract Full Text
    JAMA. 2015; 314(12):1282-1283. doi: 10.1001/jama.2015.8556

    This Clinical Evidence Synopsis summarizes a Cochrane review of trials comparing oxycodone with placebo and other opioids for treating cancer pain in adults.

  • JAMA September 22, 2015

    Figure: Pain Scores Analyzed as the Standardized Mean Difference (SMD) Between the Treatment Groups

    Source: Data were adapted with permission from Wiley. CR indicates controlled release; ER, extended release; IR, immediate release. SMD was calculated using the inverse variance fixed-effect method. The SMD can be interpreted as an effect size, with small effect size values of 0.2; medium, 0.5; and large, 0.8. The size of the data markers indicates the weight of the study.aIR oxycodone is input as the comparator group in this specific drug comparison grouping.bWeek 4 data.
  • Pediatric Oxycodone

    Abstract Full Text
    JAMA. 2015; 314(11):1108-1108. doi: 10.1001/jama.2015.11145
  • Safer Oxycodone

    Abstract Full Text
    JAMA. 2013; 309(20):2087-2087. doi: 10.1001/jama.2013.5921
  • VA Mismanagement Found

    Abstract Full Text
    JAMA. 2003; 289(21):2787-2787. doi: 10.1001/jama.289.21.2787-a
  • Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial

    Abstract Full Text
    free access is active quiz
    JAMA. 2015; 314(15):1572-1580. doi: 10.1001/jama.2015.13043

    This randomized trial compared improvement in functional outcomes among patients with low back pain discharged from the emergency department and receiving naproxen with either placebo, cyclobenzaprine, or oxycodone/acetaminophen.

  • Trends in Medical Use and Abuse of Opioid Analgesics

    Abstract Full Text
    free access
    JAMA. 2000; 283(13):1710-1714. doi: 10.1001/jama.283.13.1710
  • Interpretation of Urine Drug Screens: Metabolites and Impurities

    Abstract Full Text
    JAMA. 2017; 318(17):1704-1705. doi: 10.1001/jama.2017.10910

    A comprehensive urine drug screen for a 50-year-old woman taking daily methadone, immediate-release morphine, gabapentin, duloxetine, and celecoxib for pain was positive for methadone and morphine but also codeine and hydromorphone. How do you interpret the results?

  • Opioid vs Nonopioid Acute Pain Management in the Emergency Department

    Abstract Full Text
    JAMA. 2017; 318(17):1655-1656. doi: 10.1001/jama.2017.16725
  • Risks of Codeine and Tramadol in Children

    Abstract Full Text
    free access
    JAMA. 2017; 318(15):1514-1514. doi: 10.1001/jama.2017.13534
  • Reframing the Opioid Epidemic as a National Emergency

    Abstract Full Text
    JAMA. 2017; 318(16):1539-1540. doi: 10.1001/jama.2017.13358

    This Viewpoint discusses the president’s recent declaration of a public health emergency in response to the opioid crisis in the United States.

  • Ten Steps the Federal Government Should Take Now to Reverse the Opioid Addiction Epidemic

    Abstract Full Text
    JAMA. 2017; 318(16):1537-1538. doi: 10.1001/jama.2017.14567

    In this Viewpoint, former CDC Director Tom Frieden outlines 10 steps the federal government should take to prevent opioid addiction among nonusers and treat addiction and prevent overdoses among current users.

  • Underlying Factors in Drug Overdose Deaths

    Abstract Full Text
    free access online first
    JAMA. 2017; doi: 10.1001/jama.2017.15971

    In this Viewpoint, authors from the US CDC’s National Center for Injury Prevention and Control discuss infrastructure investments, legal changes, and clinical and public health strategies for reducing overdose deaths among opioid users.

  • Urine Drug Screens to Monitor Opioid Use for Managing Chronic Pain

    Abstract Full Text
    JAMA. 2017; 318(11):1061-1062. doi: 10.1001/jama.2017.10593

    A 53-year-old woman with chronic low back pain presented for a prescription refill of hydrocodone/acetaminophen. She had partial paralysis from a thoracic spinal cord infarction secondary to aortic dissection from prior cocaine use and reported taking hydrocodone on that day but no recent illicit drug use. Urine immunoassay drug screen results were negative overall but positive for cocaine. How would you proceed?

  • Hailey

    Abstract Full Text
    JAMA. 2016; 316(19):1975-1976. doi: 10.1001/jama.2016.10251
  • Lifesaving App for Opioid Users

    Abstract Full Text
    JAMA. 2016; 316(17):1756-1756. doi: 10.1001/jama.2016.15572